Shin Sangsu, Kim Miok, Lee Seon-Jin, Park Kang-Seo, Lee Chang Hoon
Department of Animal Biotechnology, Kyungpook National University, Sangju, Republic of Korea.
Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon, Republic of Korea.
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):349-362. doi: 10.21873/cgp.20045.
BACKGROUND/AIM: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. The ability of HCC to avoid immune detection is considered one of the main factors making it difficult to cure. Abnormal histone deacetylation is thought to be one of the mechanisms for HCC immune escape, making histone deacetylases (HDACs) attractive targets for HCC treatment. Here, we investigated the effect of trichostatin A (TSA), a highly potent HDAC inhibitor, on HCC (HepG2) gene expression and function.
A genome wide-transcriptional microarray was used to identify genes regulated by TSA in HepG2 cells. Gene Ontology was used to identify pathways regulated by TSA, and these changes were confirmed by qPCR. The effect of TSA on natural killer (NK) cell-mediated killing of HCC cell lines were analyzed by both flow cytometry and LDH cytotoxicity assay. A study was also conducted in a Balb/c nude mice xenograft model to assess the anti-tumor activity of TSA.
TSA regulated the transcription of numerous innate immunity & tumor antigen recognition-associated genes, such as ULBP1 and RAET1G, in HCC cells. In vivo, TSA reduced tumor cell growth in an NK cell-dependent manner. In vitro, TSA treatment of HepG2 cells rendered them more susceptible to NK cell-mediated killing while increasing the expression of NKGD2 ligands, including ULBP1/2/3 and MICA/B. TSA also induced direct killing of HCC cells by stimulating apoptosis.
TSA likely increases killing of HCC cells indirectly by increasing NK cell-directed killing and directly by increasing apoptosis.
背景/目的:肝细胞癌(HCC)是全球癌症相关死亡的第二大主要原因。HCC逃避免疫检测的能力被认为是其难以治愈的主要因素之一。异常的组蛋白去乙酰化被认为是HCC免疫逃逸的机制之一,这使得组蛋白去乙酰化酶(HDACs)成为HCC治疗的有吸引力的靶点。在此,我们研究了高效HDAC抑制剂曲古抑菌素A(TSA)对HCC(HepG2)基因表达和功能的影响。
使用全基因组转录微阵列来鉴定TSA在HepG2细胞中调控的基因。利用基因本体论来鉴定TSA调控的通路,并通过qPCR确认这些变化。通过流式细胞术和LDH细胞毒性测定分析TSA对自然杀伤(NK)细胞介导的HCC细胞系杀伤作用的影响。还在Balb/c裸鼠异种移植模型中进行了一项研究,以评估TSA的抗肿瘤活性。
TSA调节HCC细胞中众多先天免疫和肿瘤抗原识别相关基因的转录,如ULBP1和RAET1G。在体内,TSA以NK细胞依赖的方式减少肿瘤细胞生长。在体外,TSA处理HepG2细胞使其更容易受到NK细胞介导的杀伤,同时增加NKGD2配体的表达,包括ULBP1/2/3和MICA/B。TSA还通过刺激凋亡诱导HCC细胞的直接杀伤。
TSA可能通过增加NK细胞介导的杀伤间接增加HCC细胞的杀伤,并通过增加凋亡直接增加杀伤。